| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f4dce064add4f464596348bea6de4c5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 |
| filingDate |
1993-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf826819704be56eb95d51d3fc32b2a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb076a4d749e325ccf9eaaeaa32990f6 |
| publicationDate |
1995-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0648120-A1 |
| titleOfInvention |
Use of phosphonates for the treatment of osteoporosis |
| abstract |
A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, comprising a thirty (30) day treatment period, comprised of a high potency phosphonate compound administration regimen wherein a) said high potency phosphonate administration regimen comprises the systemic administration to said subject of a high potency phosphonate compound at a level of from 0.00001 mgP/kg to 0.1 mgP/kg per day that said high potency phosphonate compound is administered, provided that said high potency phosphonate compound is administered at least one day of every said thirty (30) day treatment period; and wherein b) said thirty (30) day treatment period may be followed by a rest period of at least one day. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8052987-B2 |
| priorityDate |
1992-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |